To print: Select File and then Print from your browser's menu

Title: Albumin-Bound Paclitaxel Approved for Metastatic Breast Cancer in China

"Albumin-Bound Paclitaxel Approved for Metastatic Breast Cancer in China"

LOS ANGELES -- July 14, 2008 -- The China State Food and Drug Administration has approved albumin-bound paclitaxel ABI-007 (Abraxane) for the treatment of breast cancer after failure of standard chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. The phase 3 clinical trials in the United States and China, on which this approval was based, demonstrated that albumin-bound paclitaxel doubled the response rate, significantly prolonged time to tumour progression, and in the US trial, significantly improved overall survival versus paclitaxel (Taxol) in the approved indication. Abraxane is a solvent-free nanoparticle including albumin that encapsulates paclitaxel. Taxol consists of the taxane in a cremophor solvent. Data from the pivotal US head-to-head trial demonstrated that albumin-bound paclitaxel nearly doubled the overall response rate versus paclitaxel and achieved a 25% improvement in time to tumour progression when compared with paclitaxel. Furthermore, patients receiving albumin-bound paclitaxel in the second-line setting had a significantly prolonged survival by an additional 27% compared with solvent-based paclitaxel. The tolerability with albumin-bound paclitaxel and paclitaxel was comparable, despite the 50% greater dose of paclitaxel administered as albumin-bound paclitaxel. A second head-to-head trial in Chinese patients with metastatic breast cancer further demonstrated the improved efficacy of albumin-bound paclitaxel compared with solvent-based paclitaxel injection. Albumin-bound paclitaxel significantly improved overall response rate versus solvent-based paclitaxel injection and achieved a 26% improvement in progression-free survival when compared to solvent-based paclitaxel injection. Both therapies had similar toxicity profiles. Albumin-bound paclitaxel is now approved for marketing in 35 countries. SOURCE: Abraxis Bioscience, Inc.

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.